Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Recommended Once-daily Dosing of Edoxaban and Rivaroxaban in Patients With Atrial Fibrillation and Renal Dysfunction, the ERENAL Study in South Korea and Taiwan

NCT07874555 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT07874555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07874555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Recommended Once-daily Dosing of Edoxaban and Rivaroxaban in Patients With Atrial Fibrillation and Renal Dysfunction, the ERENAL Study in South Korea and Taiwan
Lead sponsor
Daiichi Sankyo
Phase
Observational
Overall status
Completed
Start date
December 25, 2025
Completion date
September 25, 2026
Enrollment
8,265 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation, renal dysfunction